ANTX NASDAQ
AN2 Therapeutics, Inc.
1W: +6.6%
1M: +25.7%
3M: +341.8%
YTD: +309.9%
1Y: +276.0%
3Y: -10.6%
$4.59
+0.04 (+0.88%)
Weekly Expected Move ±10.5%
$4
$4
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$125.8M
52W Range1-6.91
Volume68,142
Avg Volume1,481,721
Beta-0.96
Dividend—
Analyst Ratings
Company Info
CEOEric E. Easom
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2022-03-25
Websitean2therapeutics.com
1800 El Camino Real
Menlo Park, CA 94027
US
Menlo Park, CA 94027
US
650-331-9090
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Aziz Kabeer | A-Award | 3,775 | — | 2026-04-10 |
| Marks Gilbert Lynn | A-Award | 3,775 | — | 2026-04-10 |
| Martin Patricia A. | A-Award | 1,192 | — | 2026-04-10 |
| Day Lucy | A-Award | 82,300 | $3.91 | 2026-03-19 |
| Day Lucy | A-Award | 73,665 | $3.91 | 2026-03-19 |